Danish Consumer Durables Stock News

Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability over the last year. The earnings release keeps that tension front and center. H1 revenue landed at DKK 4.5b, powered by a DKK 3.7b Phase III milestone and a DKK 798m payment from Roche, and management highlighted DKK 14.5b of cash on hand. The question now is how long that earnings and cash firepower can support the...

Netcompany Group stock closed at DKK327.0 on Thursday, with the market already pricing in a high growth story on a P/E of 52.3x. The latest quarter did little to settle the debate over whether that premium represents comfort or a potential cliff edge. Headline revenue for the first half reached DKK4.9b, with organic growth in the mid teens, and management raised full year revenue guidance. The catch lies in profitability. A reported net profit margin of 3.3% for the last year and a recent one...

Pandora stock has been on a tear, with a roughly 62% gain over the past three months, so expectations were already high coming into this Q2 report. The headline this time is not explosive growth but proof of resilience. Revenue reached DKK 7,219m and basic earnings per share came in at DKK 11.7, while management leaned on margin discipline and a one off tariff refund to keep profitability solid. For investors, the key question now is how that mix of steady top line and supported margins...

Netcompany Group (CPSE:NETC) reported second quarter 2026 earnings on 13 August, with both sales and net income higher than the prior year. The announcement gives investors fresh numbers to reassess the stock. See our latest analysis for Netcompany Group. Netcompany Group's latest earnings update comes after a mixed price pattern, with the share price up 6.2% over the past month yet down 6.4% year to date, while the 1 year total shareholder return of 38.0% and 3 year total shareholder return...

Jeudan stock closed at DKK204 on Thursday, only slightly higher over the past week, even though the latest figures show an attention grabbing surge in reported profitability. The headline number is a trailing net margin of 55.7%, flattered by a DKK640.8m one off gain that pushes earnings well above what the underlying rental business alone would usually support. That is the pivot investors now face. The short term story looks rich on paper. The longer term question is how that one off flows...

H+H International stock closed at DKK107 today after a solid few weeks of steady gains. The market is already pricing in some recovery, and the fresh Q2 numbers explain why sentiment has shifted. The headline is simple: after a run of losses, H+H International has reported a quarter with DKK752m in revenue and a return to profit with DKK13m of net income. The short term now meets the long term. Positive free cash flow in the first half and improving leverage sit alongside a still loss-making...

Central banks are keeping interest rates restrictive as they try to squeeze out lingering inflation. That keeps funding costs higher and puts more pressure on companies that rely heavily on borrowing. It also shines a spotlight on businesses that generate solid cash flows and still trade below estimated fair value. In this context, this article walks through three stocks from the Undervalued Stocks Based On Cash Flows screener that stand out right now. The three stocks covered below are just...

Dampskibsselskabet Norden (CPSE:DNORD) is in focus after reporting second quarter 2026 earnings, with sales of US$1,047.4 million and net income of US$100.8 million, compared with the prior year period. See our latest analysis for Dampskibsselskabet Norden. The strong second quarter earnings update appears to have coincided with firmer sentiment in Dampskibsselskabet Norden, with the share price at DKK336.8 after a 34.4% year to date share price return and a 5 year total shareholder return of...

Aktieselskabet Schouw (CPSE:SCHO) is in focus after portfolio company BioMar raised its full year 2026 revenue and EBIT guidance, with the updated figures set to flow into Schouw’s upcoming interim report. See our latest analysis for Aktieselskabet Schouw. The BioMar guidance update comes as Aktieselskabet Schouw’s share price sits at DKK633.0, with a 1-day share price return of 2.10% and a 7-day share price return of 2.93% suggesting short term momentum, while the 1-year total shareholder...

Matas stock came into today on the back foot, down about 15% over the past three months, so investors were primed for disappointment. The headline this quarter is margin pressure. Net profit margin over the last year sits at 2.8%, lower than the 3.4% level a year earlier, even as trailing revenue is DKK 8.8b. That combination of modest revenue progress and thinner profitability is what the market is reacting to. The key question for you is whether today’s price move reflects a measured...

Vestas Wind Systems heads into this earnings season with the stock at DKK211.8 after a strong run over the past week and quarter. The market has already priced in optimism. The question now is whether the latest numbers justify that confidence. The headline from Q2 is clear. Revenue reached €4.7b and the EBIT margin before special items came in at 9.4%, helped by a strong performance in Power Solutions and a higher full year EBIT margin guidance range of 7% to 9%. For a capital intensive wind...

When ships pay up to US$4 million just to jump the queue at the Panama Canal, it is a signal that global trade routes are under real strain and that money is being made and lost in unexpected corners of the market. That kind of stress can reshape pricing power, contract terms, and customer relationships. This article walks through three freight forwarding and 3PL stocks that are closely tied to this story and explains how the same news can create very different risk and reward profiles for...

Demant walked into this earnings day with momentum on its side. The stock is up about 22% over the past three months and trading near DKK288.6, helped by a P/E below key hearing care peers despite a strong run. The headline from this report is not the growth story that many investors were leaning on. It is the squeeze in profitability. Net profit margins over the last year sit near 10.3%, lower than the prior year, which jars with a share price that had been pricing in cleaner earnings...

European equities have recently experienced a boost, with the pan-European STOXX Europe 600 Index climbing 1.70% due to improved risk appetite and resilient earnings, despite ongoing geopolitical uncertainties. In this environment of cautious optimism, identifying undervalued stocks can be a strategic move for investors seeking opportunities that are priced below their estimated worth.

The market had ISS sitting quietly at DKK285 going into these H1 numbers, with the stock barely moving over the past week. The earnings story is louder than the price action. Revenue for the trailing twelve months stands at DKK87.8b and net income is DKK2.8b, which keeps the net margin at about 3.2%. The key tension is that investors see a facilities services business with modest profitability and a high debt load, yet trading on a P/E of 16x while peers trade on much higher multiples. That...

NTG Nordic Transport Group stock comes into this earnings print with strong recent momentum, up about 39% over three months and trading at DKK266 at Monday’s close. The market has been rewarding the story. The headline from the quarter is clear for a freight and logistics company. Organic revenue growth in Q2 reached 14.8% and adjusted EBIT for the first half of 2026 rose 23% as NTG tightened full year EBIT guidance to a range of DKK625 to DKK650m. Short term price strength now meets a profit...

Russia’s war in Ukraine has turned European energy into a pressure point again, with supply routes, winter demand and sanctions all back in focus. That mix of risk and rearranged trade flows can quickly change how investors look at European Energy Sector stocks. This article walks through three stocks from our screener that appear positively exposed to the latest news, and explains what makes each one worth a closer look now. The three European energy stocks highlighted below are just a...

It looks like Novo Nordisk A/S ( CPH:NOVO B ) is about to go ex-dividend in the next two days. The ex-dividend date is...

How the latest earnings and guidance update set the tone for Ringkjøbing Landbobank Ringkjøbing Landbobank (CPSE:RILBA) just reported half year 2026 earnings alongside a higher full year net profit outlook, giving investors fresh numbers on profitability, income trends and credit quality. The bank posted net interest income of DKK 1,341.78 million for the half year, compared with DKK 1,411.67 million a year earlier. Net income for the same period was DKK 1,193.57 million, slightly above the...

Quite a few insiders have dramatically grown their holdings in H. Lundbeck A/S ( CPH:HLUN B ) over the past 12 months...

DFDS (CPSE:DFDS) is in focus after announcing that Mathieu Girardin will step down as EVP and Head of the Ferry Division on 14 August 2026. CEO Michael Hansen will take over interim control. See our latest analysis for DFDS. At a share price of DKK130.2, DFDS has seen firm short term momentum, with a 7 day share price return of 4.58% and 30 day return of 11.00%. However, the 3 year total shareholder return is down 41.35%, which points to a longer term reset in investor expectations as...

Novo Nordisk (CPSE:NOVO B) is back in focus after reporting second quarter results that paired GLP-1 driven sales growth and a higher full year outlook with fresh legal, clinical and partnership updates. See our latest analysis for Novo Nordisk. Novo Nordisk’s latest earnings, dividend affirmation and completed buyback come after a mixed share price run, with a 1-day share price return of 3.92% contrasting with a year-to-date share price decline of 7.62% and a 3-year total shareholder return...

Genmab guidance change and recent earnings at a glance Genmab (CPSE:GMAB) has raised its 2026 revenue outlook following second quarter results, alongside regulatory progress in Europe and positive Phase III data for key pipeline drugs that broaden its revenue base beyond DARZALEX. See our latest analysis for Genmab. Genmab’s near term momentum has picked up, with a 6.5% 1 day share price return and 20.5% 90 day share price return, while the 1 year total shareholder return of 44.7% contrasts...

It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...